PALACE: Cemiplimab Trial According to ctDNA Levels
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Paclitaxel
Related studies linked through entity extraction aliases.
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
- Status
- RECRUITING
- Phase
- PHASE3
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
- Status
- RECRUITING
- Phase
- PHASE2
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE3
QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Status
- RECRUITING
- Phase
- PHASE3
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- Status
- WITHDRAWN
- Phase
- PHASE2
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
- Status
- RECRUITING
- Phase
- PHASE2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Status
- RECRUITING
- Phase
- PHASE2
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
- Status
- RECRUITING
- Phase
- PHASE2
Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2